Tonix Pharmaceuticals Nasdaq

TNXP

US8902608624

Pharmaceuticals

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-02-04 pm EST			5-day change	1st Jan Change
0.3222 ^USD	-2.36%		+2.32%	-20.05%

Jul. 09	Tonix Pharmaceuticals Prices $4 Million Public Offering; Shares Plunge	MT
Jul. 09	Tonix Pharmaceuticals Holding Corp. announced that it expects to receive $30 million in funding	CI

Tonix Pharmaceuticals Holding Corp. announces an Equity Buyback for $12.5 million worth of its shares.

January 25, 2023 at 07:00 am EST

Tonix Pharmaceuticals Holding Corp. (NasdaqCM:TNXP) announces a share repurchase program. Under the program, the company will repurchase up to $12.5 million worth of common stock.

The company intends to fund the repurchases with available cash.

Latest news about Tonix Pharmaceuticals

Tonix Pharmaceuticals Prices $4 Million Public Offering; Shares Plunge	Jul. 09	MT
Tonix Pharmaceuticals Holding Corp. announced that it expects to receive $30 million in funding	Jul. 08	CI
Tonix Pharmaceuticals Intends to Offer and Sell Shares of its Common Stock	Jul. 08	CI
Tonix Pharmaceuticals Plans Stock Offering; Shares Fall After-Hours	Jul. 08	MT
Tonix Pharmaceuticals Gets FDA Nod to Proceed With New Drug Application for Tonmya in Fibromyalgia	Jul. 08	MT
Tonix Pharmaceuticals Reports Final Positive Pre-NDA Meeting with FDA for Tonmya? for the Management of Fibromyalgia	Jul. 08	CI
Tonix Pharmaceuticals Receives Up to $34 Million U.S. Department of Defense Contract for Accelerated Development of Broad-Spectrum Antiviral Program	Jul. 01	CI
Tonix Pharmaceuticals Closes $4 Million Offering	Jun. 28	MT
Top Midday Decliners	Jun. 27	MT
Wall Street Set to Open Marginally Lower Thursday as Investors Parse Bullish Economic Data	Jun. 27	MT
US Futures Trend Lower Pre-Bell as Investors Await Slew of Economic Data	Jun. 27	MT
Top Premarket Decliners	Jun. 27	MT
Tonix Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Rule	Jun. 26	MT
Tonix Pharmaceuticals Holding Corp. Presents Vaccine Platform Data in Keynote Talk At the Vaccine Congress 2024	Jun. 25	CI
Tonix Pharmaceuticals Holding Corp. Announces Positive Pre-NDA CMC Meeting with FDA for Tonmya for the Management of Fibromyalgia	Jun. 20	CI
Top Midday Decliners	Jun. 12	MT
Wall Street Set to Open Higher Wednesday as Key Inflation Data Lower Than Expected	Jun. 12	MT
US Futures Slightly Higher Ahead of Fed's Rate Decision, Key Inflation Data	Jun. 12	MT
Top Premarket Decliners	Jun. 12	MT
Tonix Pharmaceuticals Plans Common Stock Offering to Fund New Drug Application for Fibromyalgia; Shares Fall After Hours	Jun. 11	MT
Tonix Pharmaceuticals to Implement 1-for-32 Reverse Stock Split -- Shares Fall	Jun. 06	MT
Tonix Pharmaceuticals Holding Corp. Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500	Jun. 06	CI
ToniTonix Pharmaceuticals Holding Corp. Presents New Data on Tonmya Suggesting Activity for Improvement in Fibromyalgia-Associated Depression Severity in an Oral Presentation at ASCP Annual Meeting	Jun. 03	CI
Tranche Update on Tonix Pharmaceuticals Holding Corp.'s Equity Buyback Plan announced on January 25, 2023.	May. 13	CI
Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include Tonmya (TNX-102 SL), TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801 and TNX-1800. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.

Sector

Pharmaceuticals

Calendar

2024-08-04 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Tonix Pharmaceuticals

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.6108 USD

Average target price

94.93 USD

Spread / Average Target

+15,442.46%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
TONIX PHARMACEUTICALS	-20.05%	10.66M
CSL LIMITED	+7.46%	100B
SAMSUNG BIOLOGICS CO.,LTD.	+11.97%	42.34B
BIOGEN INC.	-11.76%	32.76B
UCB	+79.34%	29.46B
BIOMARIN PHARMACEUTICAL INC.	-12.20%	16.31B
INCYTE CORPORATION	+4.00%	14.39B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-1.90%	12.23B
ALTEOGEN INC.	+178.17%	10.47B
SWEDISH ORPHAN BIOVITRUM AB	+1.80%	8.97B

Biopharmaceuticals

Tonix Pharmaceuticals Nasdaq

Equities

TNXP

US8902608624

Pharmaceuticals

Tonix Pharmaceuticals Holding Corp. announces an Equity Buyback for $12.5 million worth of its shares.

Latest news about Tonix Pharmaceuticals

Chart Tonix Pharmaceuticals

Company Profile

Income Statement Evolution

Ratings for Tonix Pharmaceuticals

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals